• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Shockwave Medical Provides Quarterly Earnings Release Dates for 2024

    1/8/24 8:00:00 AM ET
    $SWAV
    Medical/Dental Instruments
    Health Care
    Get the next $SWAV alert in real time by email

    SANTA CLARA, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- January 8, 2024 – Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that it expects to issue quarterly earnings releases after the market closes and hold conference calls at the times indicated on the following dates:

    Fourth Quarter 2023 Earnings – Thursday, February 15, 2024 at 4:30 p.m. (ET)

    First Quarter 2024 Earnings – Monday, May 6, 2024 at 4:30 p.m. (ET)

    Second Quarter 2024 Earnings – Monday, August 5, 2024 at 4:30 p.m. (ET)

    Third Quarter 2024 Earnings – Monday, November 4, 2024 at 4:30 p.m. (ET)

    Investors interested in listening to the fourth quarter 2023 earnings conference call at 4:30 p.m. eastern time on Thursday, February 15, 2024, may do so by dialing (877) 704-4453 for domestic callers or (201) 389-0920 for international callers, using conference ID: 13742096. Live and archived webcasts of all earnings events will also be made available at https://ir.shockwavemedical.com.

    Dial-in information for future earnings calls will be provided at later dates.

    About Shockwave Medical, Inc.

    Shockwave Medical is a leader in the development and commercialization of innovative products that are transforming the treatment of cardiovascular disease. Its first-of-its-kind Intravascular Lithotripsy (IVL) technology has transformed the treatment of atherosclerotic cardiovascular disease by safely using sonic pressure waves to disrupt challenging calcified plaque, resulting in significantly improved patient outcomes. Shockwave has also recently acquired the Neovasc Reducer, which is under clinical investigation in the United States and is CE Marked in Europe. By redistributing blood flow within the heart, the Reducer is designed to provide relief to the millions of patients worldwide suffering from refractory angina. Learn more at www.shockwavemedical.com and www.neovasc.com.

    Media Contact:

    Scott Shadiow

    [email protected]

    Investor Contact:

    Debbie Kaster

    [email protected]



    Primary Logo

    Get the next $SWAV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SWAV

    DatePrice TargetRatingAnalyst
    4/5/2024Outperform → Peer Perform
    Wolfe Research
    3/27/2024$368.00Buy
    CL King
    9/29/2023$218.00Neutral
    UBS
    7/10/2023$291.00 → $335.00Equal-Weight → Overweight
    Morgan Stanley
    5/30/2023$291.00Equal-Weight
    Morgan Stanley
    3/15/2023$240.00Buy
    Needham
    12/16/2022$285.00Buy
    Deutsche Bank
    12/12/2022$300.00 → $235.00Overweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $SWAV
    Financials

    Live finance-specific insights

    See more
    • Shockwave Medical Reports First Quarter 2024 Financial Results

      SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended March 31, 2024. "The solid growth in the first quarter across geographies and products is a testament to the continued demand for our innovative solutions, driven by the unrelenting and extraordinary performance of our global Shockwave teams," said Doug Godshall, President and Chief Executive Officer of Shockwave Medical. "Our team is looking forward to continuing our mission as part of Johnson & Johnson and to

      5/6/24 4:05:00 PM ET
      $JNJ
      $SWAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Johnson & Johnson to Acquire Shockwave Medical

      Enhances Johnson & Johnson's Ability to Transform the Treatment Landscape for Cardiovascular Disease and Continue to Improve Patient Outcomes Extends Johnson & Johnson MedTech's Position in Highest-Growth, Innovation-Oriented Segments of Cardiovascular Intervention Accelerates Sales Growth and Accretive to Operating Margin for Both Johnson & Johnson and Johnson & Johnson MedTech Conference Call at 8:30 a.m. ET To Discuss Details of the Transaction Johnson & Johnson (NYSE:JNJ) and Shockwave Medical, Inc. (NASDAQ:SWAV) ("Shockwave") today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335

      4/5/24 6:31:00 AM ET
      $JNJ
      $SWAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Shockwave Medical Reports Fourth Quarter and Full Year 2023 Financial Results

      SANTA CLARA, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months and full year ended December 31, 2023. Recent Highlights Recognized revenue of $203.0 million for the fourth quarter of 2023 and $730.2 million for the full year 2023, representing increases of 41% and 49%, respectively, from the same periods in 2022Initiated the full U.S. commercial launch of the Shockwave C2+ Coronary Intravascular Lithotripsy (IVL) catheterGranted new physician and hospital reimbursement for

      2/15/24 4:03:00 PM ET
      $SWAV
      Medical/Dental Instruments
      Health Care

    $SWAV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ShockWave Medical downgraded by Wolfe Research

      Wolfe Research downgraded ShockWave Medical from Outperform to Peer Perform

      4/5/24 7:33:47 AM ET
      $SWAV
      Medical/Dental Instruments
      Health Care
    • CL King initiated coverage on ShockWave Medical with a new price target

      CL King initiated coverage of ShockWave Medical with a rating of Buy and set a new price target of $368.00

      3/27/24 8:20:17 AM ET
      $SWAV
      Medical/Dental Instruments
      Health Care
    • UBS initiated coverage on ShockWave Medical with a new price target

      UBS initiated coverage of ShockWave Medical with a rating of Neutral and set a new price target of $218.00

      9/29/23 7:46:27 AM ET
      $SWAV
      Medical/Dental Instruments
      Health Care

    $SWAV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by ShockWave Medical Inc. (Amendment)

      SC 13G/A - Shockwave Medical, Inc. (0001642545) (Subject)

      2/13/24 5:13:59 PM ET
      $SWAV
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by ShockWave Medical Inc. (Amendment)

      SC 13G/A - Shockwave Medical, Inc. (0001642545) (Subject)

      2/9/24 9:49:30 AM ET
      $SWAV
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by ShockWave Medical Inc.

      SC 13G - Shockwave Medical, Inc. (0001642545) (Subject)

      2/8/24 10:17:35 AM ET
      $SWAV
      Medical/Dental Instruments
      Health Care

    $SWAV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bruker Appoints Laura Francis to its Board of Directors

      Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

      2/21/25 8:00:00 AM ET
      $BRKR
      $PGNY
      $SIBN
      $SWAV
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Misc Health and Biotechnology Services
      Health Care
    • Deborah Kilpatrick Joins Sonder Capital as its Newest Venture Partner

      SAN CARLOS, Calif., Oct. 28, 2024 /PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced the addition of Deborah Kilpatrick, Ph.D., former CEO of Evidation Health and co-founder of MedtechWomen, as a Venture Partner. Kilpatrick earned her Ph.D. from Georgia Tech in mechanical engineering with a focus in bioengineering and a minor in applied mathematics. Most recently, she was the CEO and Executive Chair of the Board at Evidation Health, a technology company that pioneered th

      10/28/24 7:00:00 AM ET
      $ISRG
      $PRCT
      $SNBR
      $SWAV
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
      Home Furnishings
    • Sarepta Therapeutics Set to Join S&P MidCap 400

      NEW YORK, May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector June 3, 2024 S&P MidCap 400 Addition Sarepta Therapeutics SRPT Health Care June 3, 2024 S&P MidCap 400 Deletion Shockwave Medical SWAV Health Care For

      5/29/24 5:48:00 PM ET
      $JNJ
      $SPGI
      $SRPT
      $SWAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Finance: Consumer Services
      Finance

    $SWAV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Francis Laura returned 4,784 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Shockwave Medical, Inc. (0001642545) (Issuer)

      5/31/24 4:42:11 PM ET
      $SWAV
      Medical/Dental Instruments
      Health Care
    • Moll Frederic H returned 287,521 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Shockwave Medical, Inc. (0001642545) (Issuer)

      5/31/24 4:41:41 PM ET
      $SWAV
      Medical/Dental Instruments
      Health Care
    • Papiernik Antoine returned 34,913 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Shockwave Medical, Inc. (0001642545) (Issuer)

      5/31/24 4:40:07 PM ET
      $SWAV
      Medical/Dental Instruments
      Health Care

    $SWAV
    SEC Filings

    See more
    • SEC Form 15-12G filed by Shockwave Medical Inc.

      15-12G - Shockwave Medical, Inc. (0001642545) (Filer)

      6/10/24 4:33:25 PM ET
      $SWAV
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by Shockwave Medical Inc.

      S-8 POS - Shockwave Medical, Inc. (0001642545) (Filer)

      5/31/24 4:38:18 PM ET
      $SWAV
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by Shockwave Medical Inc.

      S-8 POS - Shockwave Medical, Inc. (0001642545) (Filer)

      5/31/24 4:28:57 PM ET
      $SWAV
      Medical/Dental Instruments
      Health Care

    $SWAV
    Leadership Updates

    Live Leadership Updates

    See more
    • Bruker Appoints Laura Francis to its Board of Directors

      Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

      2/21/25 8:00:00 AM ET
      $BRKR
      $PGNY
      $SIBN
      $SWAV
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Misc Health and Biotechnology Services
      Health Care
    • Deborah Kilpatrick Joins Sonder Capital as its Newest Venture Partner

      SAN CARLOS, Calif., Oct. 28, 2024 /PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced the addition of Deborah Kilpatrick, Ph.D., former CEO of Evidation Health and co-founder of MedtechWomen, as a Venture Partner. Kilpatrick earned her Ph.D. from Georgia Tech in mechanical engineering with a focus in bioengineering and a minor in applied mathematics. Most recently, she was the CEO and Executive Chair of the Board at Evidation Health, a technology company that pioneered th

      10/28/24 7:00:00 AM ET
      $ISRG
      $PRCT
      $SNBR
      $SWAV
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
      Home Furnishings
    • Sarepta Therapeutics Set to Join S&P MidCap 400

      NEW YORK, May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector June 3, 2024 S&P MidCap 400 Addition Sarepta Therapeutics SRPT Health Care June 3, 2024 S&P MidCap 400 Deletion Shockwave Medical SWAV Health Care For

      5/29/24 5:48:00 PM ET
      $JNJ
      $SPGI
      $SRPT
      $SWAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Finance: Consumer Services
      Finance